Practice Efficiency and Total Cost of Care with Bispecifics and CAR-T in Relapsed/refractory Diffuse Large B-cell Lymphoma: an Institutional Perspective

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jun 24

PMID 38913826

Authors

Matthew Lei

Qianyi Li

Ken ODay

Kellie Meyer

Anthony Wang

Monika P Jun

Affiliations

Soon will be listed here.

Abstract

Novel treatment options for relapsed/refractory diffuse large B-cell lymphoma include T-cell targeting therapies. Practice efficiency and cost are important for informed treatment decisions. An institutional decision-maker cost model was developed for 6-month, 1-year and median cycles of treatment time horizons comparing practice efficiency and costs of epcoritamab vs glofitamab and axicabtagene ciloleucel (axi-cel). Overall, epcoritamab required the shortest personnel and chair time, except over 1 year (second shortest chair time). Across all time horizons, epcoritamab was cost-saving vs axi-cel and had similar costs to glofitamab on a per-month basis. Epcoritamab reduced personnel and chair time. Additionally, epcoritamab was cost-saving vs axi-cel and had similar costs to glofitamab on a per-month basis.

References

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Epstein R . Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs. Clinicoecon Outcomes Res. 2021; 13:801-807. PMC: 8439384. DOI: 10.2147/CEOR.S317687. View

Drill E, Qiu A, Shapouri S, To T, Ravelo A, Schade J . Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab. Oncology (Williston Park). 2022; 35(12):804-811. DOI: 10.46883/2021.25920935. View

North R, Harvey V, Cox L, Ryan S . Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015; 7:423-30. PMC: 4524269. DOI: 10.2147/CEOR.S85599. View

Shulman L, Sheldon L, Benz E . The Future of Cancer Care in the United States-Overcoming Workforce Capacity Limitations. JAMA Oncol. 2020; 6(3):327-328. DOI: 10.1001/jamaoncol.2019.5358. View

Teras L, DeSantis C, Cerhan J, Morton L, Jemal A, Flowers C . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459. DOI: 10.3322/caac.21357. View

McCloskey C, Ortega M, Nair S, Garcia M, Manevy F . A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. Pharmacoecon Open. 2022; 7(1):3-36. PMC: 9395845. DOI: 10.1007/s41669-022-00361-3. View

Alderuccio J, Sharman J . ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Rev. 2022; 56:100967. DOI: 10.1016/j.blre.2022.100967. View

Sehn L, Salles G . Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384(9):842-858. PMC: 8377611. DOI: 10.1056/NEJMra2027612. View

10.

Slavcev M, Spinelli A, Absalon E, Masterson T, Heuck C, Lam A . Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma. Clinicoecon Outcomes Res. 2021; 13:465-473. PMC: 8197571. DOI: 10.2147/CEOR.S302682. View

11.

Nedved A, Maddocks K, Nowakowski G . Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Oncologist. 2023; 28(3):199-207. PMC: 10020798. DOI: 10.1093/oncolo/oyac256. View

12.

Anderson K, Landgren O, Arend R, Chou J, Jacobs I . Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019; 15(28):3267-3281. DOI: 10.2217/fon-2019-0368. View

13.

Pierce C, Baker J . A nursing process model: quantifying infusion therapy resource consumption. J Infus Nurs. 2004; 27(4):232-44. DOI: 10.1097/00129804-200407000-00008. View

14.

Rule S, Collins G, Samanta K . Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014; 17(7):459-68. DOI: 10.3111/13696998.2014.914033. View

15.

Barbee M, Harvey R, Lonial S, Kaufman J, Wilson N, McKibbin T . Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013; 47(9):1136-42. DOI: 10.1177/1060028013503122. View

16.

Rahib L, Wehner M, Matrisian L, Nead K . Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021; 4(4):e214708. PMC: 8027914. DOI: 10.1001/jamanetworkopen.2021.4708. View

17.

Takvorian S, Balogh E, Nass S, Valentin V, Hoffman-Hogg L, Oyer R . Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action. J Natl Cancer Inst. 2019; 112(7):663-670. PMC: 7357321. DOI: 10.1093/jnci/djz239. View

18.

Shinder G, Paradis P, Posman M, Mishagina N, Guay M, Linardos D . Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study. BMC Health Serv Res. 2012; 12:370. PMC: 3519524. DOI: 10.1186/1472-6963-12-370. View

19.

De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella A . Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries. PLoS One. 2016; 11(6):e0157957. PMC: 4928781. DOI: 10.1371/journal.pone.0157957. View

20.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M . Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5):431-40. DOI: 10.1016/S1470-2045(11)70081-X. View